Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent
- 23 May 2006
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (21) , 8078-8083
- https://doi.org/10.1073/pnas.0601192103
Abstract
Genetic abnormalities that result in expression of chimeric tyrosine kinase proteins such as BCR-ABL1 and ETV6-PDGFRbeta are common causes of hematopoietic malignancies. The paradigm for constitutive activation of these fusion tyrosine kinases is enforced homodimerization by self-association domains present in the fusion partner proteins. The unique interstitial deletion on chromosome 4q12 that leads to expression of the FIP1L1-PDGFRalpha fusion tyrosine kinase was recently identified as a cause of chronic eosinophilic leukemia. In this report, we demonstrate that FIP1L1 is completely dispensable for PDGFRalpha activation in vitro and in vivo. Instead, truncation of PDGFRalpha between two conserved tryptophan residues in the juxtamembrane (JM) domain is required for kinase activation and transforming potential of FIP1L1-PDGFRalpha. The presence of a complete JM domain in FIP1L1-PDGFRalpha is inhibitory, but this autoinhibition can be overcome by enforced homodimerization. Similar effects of the JM domain in the context of PDGFRbeta were observed. These results suggest that disruption of the autoinhibitory JM domain is an alternative, dimerization-independent mechanism by which chimeric tyrosine kinases are constitutively activated and induce leukemogenesis.Keywords
This publication has 29 references indexed in Scilit:
- Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogeneticsLeukemia, 2005
- Juxtamembrane autoinhibition in receptor tyrosine kinasesNature Reviews Molecular Cell Biology, 2004
- Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemiasLeukemia, 2004
- The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane DomainMolecular Cell, 2004
- Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinaseProceedings of the National Academy of Sciences, 2003
- Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane RegionMolecular and Cellular Biology, 2003
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- Definition of an Inhibitory Juxtamembrane WW-like Domain in the Platelet-derived Growth Factor β ReceptorJournal of Biological Chemistry, 2002
- The roles of FLT3 in hematopoiesis and leukemiaBlood, 2002
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998